MARKET

ASND

ASND

Ascendis Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

113.41
+0.26
+0.23%
Closed 16:00 03/27 EDT
OPEN
110.15
PREV CLOSE
113.15
HIGH
116.37
LOW
108.93
VOLUME
189.78K
TURNOVER
--
52 WEEK HIGH
145.59
52 WEEK LOW
90.06
MARKET CAP
5.41B
P/E (TTM)
-27.5027
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ASND and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 12 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ASND stock price target is 167.06 with a high estimate of 203.39 and a low estimate of 142.07.

EPS

ASND News

More
  • Ascendis Pharma A/S Announces Full Year 2019 Financial Results and Business Update Conference Call on April 1
  • GlobeNewswire · 4d ago
  • Hedge Funds Have Never Been This Bullish On Ascendis Pharma A/S (ASND)
  • Insider Monkey · 03/23 01:25
  • We're Hopeful That Ascendis Pharma (NASDAQ:ASND) Will Use Its Cash Wisely
  • Simply Wall St. · 03/21 13:49
  • Piper Sandler likes Gilead ahead of expected FDA nod for remdesivir for Covid-19
  • Seeking Alpha - Article · 03/20 11:12

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About ASND

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.
More

Webull offers kinds of Ascendis Pharma A/S stock information, including NASDAQ:ASND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASND stock news, and many more online research tools to help you make informed decisions.